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Background: Positive association between obesity and survival after breast cancer was demonstrated in previous
meta-analyses of published data, but only the results for the comparison of obese versus non-obese was summarised.
Methods: We systematically searched in MEDLINE and EMBASE for follow-up studies of breast cancer survivors with
body mass index (BMI) before and after diagnosis, and total and cause-speciﬁc mortality until June 2013, as part of the
World Cancer Research Fund Continuous Update Project. Random-effects meta-analyses were conducted to explore
the magnitude and the shape of the associations.
Results: Eighty-two studies, including 213 075 breast cancer survivors with 41 477 deaths (23 182 from breast cancer)
were identiﬁed. For BMI before diagnosis, compared with normal weight women, the summary relative risks (RRs) of total
mortality were 1.41 [95% conﬁdence interval (CI) 1.29–1.53] for obese (BMI >30.0), 1.07 (95 CI 1.02–1.12) for overweight
(BMI 25.0–<30.0) and 1.10 (95% CI 0.92–1.31) for underweight (BMI <18.5) women. For obese women, the summary
RRs were 1.75 (95% CI 1.26–2.41) for pre-menopausal and 1.34 (95% CI 1.18–1.53) for post-menopausal breast
cancer. For each 5 kg/m2 increment of BMI before, <12 months after, and ≥12 months after diagnosis, increased risks of
17%, 11%, and 8% for total mortality, and 18%, 14%, and 29% for breast cancer mortality were observed, respectively.
Conclusions: Obesity is associated with poorer overall and breast cancer survival in pre- and post-menopausal breast
cancer, regardless of when BMI is ascertained. Being overweight is also related to a higher risk of mortality. Randomised
clinical trials are needed to test interventions for weight loss and maintenance on survival in women with breast cancer.
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introduction
The number of female breast cancer survivors is growing because
of longer survival as a consequence of advances in treatment and
early diagnosis. There were ∼2.6 million female breast cancer sur-
vivors in US in 2008 [1], and in the UK, breast cancer accounted
for ∼28% of the 2 million cancer survivors in 2008 [2].
Obesity is a pandemic health concern, with over 500 million
adults worldwide estimated to be obese and 958 million were
overweight in 2008 [3]. One of the established risk factors for
breast cancer development in post-menopausal women is
obesity [4], which has further been linked to breast cancer recur-
rence [5] and poorer survival in pre- and post-menopausal
breast cancer [6, 7]. Preliminary ﬁndings from randomised, con-
trolled trials suggest that lifestyle modiﬁcations improved bio-
markers associated with breast cancer progression and overall
survival [8].
The biological mechanisms underlying the association between
obesity and breast cancer survival are not established, and could
involve interacting mediators of hormones, adipocytokines, and
inﬂammatory cytokines which link to cell survival or apoptosis,
migration, and proliferation [9]. Higher level of oestradiol pro-
duced in postmenopausal women through aromatisation of
androgens in the adipose tissues [10], and higher level of insulin
[11], a condition common in obese women, are linked to poorer
prognosis in breast cancer. A possible interaction between leptin
and insulin [12], and obesity-related markers of inﬂammation
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[13] have also been linked to breast cancer outcomes. Non-bio-
logical mechanisms could include chemotherapy under-dosing in
obese women, suboptimal treatment, and obesity-related compli-
cations [14].
Numerous studies have examined the relationship between
obesity and breast cancer outcomes, and past reviews have con-
cluded that obesity is linked to a lower survival; however, when
investigated in a meta-analysis of published data, only the results
of obese compared with non-obese or lighter women were
summarised [6, 7, 15].
We carried out a systematic literature review and meta-ana-
lysis of published studies to explore the magnitude and the
shape of the association between body fatness, as measured by
body mass index (BMI), and the risk of total and cause-speciﬁc
mortality, overall and in women with pre- and post-menopausal
breast cancer. As body weight may change close to diagnosis
and during primary treatment of breast cancer [16], we exam-
ined BMI in three periods: before diagnosis, <12 months after
diagnosis, and ≥12 months after breast cancer diagnosis.
materials andmethods
data sources and search
We carried out a systematic literature search, limited to publica-
tions in English, for articles on BMI and survival in women with
breast cancer in OVID MEDLINE and EMBASE from inception
to 30 June 2013 using the search strategy implemented for the
WCRF/AICR Continuous Update Project on breast cancer sur-
vival. The search strategy contained medical subject headings and
text words that covered a broad range of factors on diet, physical
activity, and anthropometry. The protocol for the review is
available at http://www.dietandcancerreport.org/index.php [17].
In addition, we hand-searched the reference lists of relevant arti-
cles, reviews, and meta-analysis papers.
study selection
Included were follow-up studies of breast cancer survivors,
which reported estimates of the associations of BMI ascertained
before and after breast cancer diagnosis with total or cause-
speciﬁc mortality risks. Studies that investigated BMI after diag-
nosis were divided into two groups: BMI <12 months after diag-
nosis (BMI <12 months) and BMI 12 months or more after
diagnosis (BMI ≥12 months). Outcomes included total mortal-
ity, breast cancer mortality, death from cardiovascular disease,
and death from causes other than breast cancer. When multiple
publications on the same study population were found, results
based on longer follow-up and more outcomes were selected for
the meta-analysis.
data extraction
DSMC, TN, and DA conducted the search. DSMC, ARV, and
DNR extracted the study characteristics, tumour-related infor-
mation, cancer treatment, timing and method of weight and
height assessment, BMI levels, number of outcomes and popula-
tion at-risk, outcome type, estimates of association and their
measure of variance [95% conﬁdence interval (CI) or P value],
and adjustment factors in the analysis.
statistical analysis
Categorical and dose–response meta-analyses were conducted
using random-effects models to account for between-study het-
erogeneity [18]. Summary relative risks (RRs) were estimated
using the average of the natural logarithm of the RRs of each
study weighted by the inverse of the variance and then
unweighted by applying a random-effects variance component
which is derived from the extent of variability of the effect sizes
of the studies. The maximally adjusted RR estimates were used
for the meta-analysis except for the follow-up of randomised,
controlled trials [19, 20] where unadjusted results were also
included, as these studies mostly involved a more homogeneous
study population. BMI or Quetelet’s Index (QI) measured in
units of kg/m2 was used.
We conducted categorical meta-analyses by pooling the cat-
egorical results reported in the studies. The studies used differ-
ent BMI categories. In some studies, underweight (BMI <18.5
kg/m2 according to WHO international classiﬁcation) and
normal weight women (BMI 18.5–<25.0 kg/m2) were classiﬁed
together but, in some studies, they were classiﬁed separately.
Similarly, most studies classiﬁed overweight (BMI 25.0–<30.0
kg/m2) and obese (BMI ≥30.0 kg/m2) women separately but, in
some studies, overweight and obese women were combined. The
reference category was normal weight or underweight together
with normal weight, depending on the studies. For convenience,
the BMI categories are referred to as underweight, normal
weight, overweight, and obese in the present review. We derived
the RRs for overweight and obese women compared with
normal weight women in two studies [19, 21] that had more
than four BMI categories using the method of Hamling et al.
[22]. Studies that reported results for obese compared with non-
obese women were analysed separately.
The non-linear dose–response relationship between BMI and
mortality was examined using the best-ﬁtting second-order frac-
tional polynomial regression model [23], deﬁned as the one
with the lowest deviance. Non-
linearity was tested using the likelihood ratio test [24]. In the
non-linear meta-analysis, the reference category was the lowest
BMI category in each study and RRs were recalculated using the
method of Hamling et al. [22] when the reference category was
not the lowest BMI category in the study.
We also conducted linear dose–response meta-analyses, ex-
cluding the category underweight when reported separately in
the studies, by pooling estimates of RR per unit increase (with
its standard error) provided by the studies, or derived by us
from categorical data using generalised least-squares for trend
estimation [25]. To estimate the trend, the numbers of
outcomes and population at-risk for at least three BMI categor-
ies, or the information required to derive them using standard
methods [26], and means or medians of the BMI categories, or
if not reported in the studies, the estimated midpoints of the cat-
egories had to be available. When the extreme BMI categories
were open-ended, we used the width of the adjacent close-ended
category to estimate the midpoints. Where the RRs were pre-
sented by subgroups (age group [27], menopausal status [28,
29], stage [30] or subtype [31] of breast cancer, or others [32–
34]), an overall estimate for the study was obtained by a ﬁxed-
effect model before pooling in the meta-analysis. We estimated
the risk increase of death for an increment of 5 kg/m2 of BMI.
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To assess heterogeneity, we computed the Cochran Q test and
I2 statistic [35]. The cut points of 30% and 50% were used for
low, moderate, and substantial level of heterogeneity. Sources of
heterogeneity were explored by meta-regression and subgroup
analyses using pre-deﬁned factors, including indicators of study
quality (menopausal status, hormone receptor status, number of
outcomes, length of follow-up, study design, geographic loca-
tion, BMI assessment, adjustment for confounders, and others).
Small study or publication bias was examined by Egger’s test
[36] and visual inspection of the funnel plots. The inﬂuence of
each individual study on the summary RR was examined by ex-
cluding the study in turn [37]. A P value of <0.05 was consid-
ered statistically signiﬁcant. All analyses were conducted using
Stata version 12.1 (Stata Statistical Software: Release 12,
StataCorp LP, College Station, TX).
results
A total of 124 publications investigating the relationship of body
fatness and mortality in women with breast cancer were iden-
tiﬁed. We excluded 31 publications, including four publications
on other obesity indices [38–41], 12 publications without a
measure of association [42–53], and 15 publications superseded
by publications of the same study with more outcomes [54–68].
A further 14 publications were excluded because of insufﬁcient
data for the meta-analysis (ﬁve publications [69–73]) or un-
adjusted results (nine publications [74–82]), from which nine
publications reported statistically signiﬁcant increased risk of
total, breast cancer or non-breast cancer mortality in obese
women (before or <12 months after diagnosis) compared with
the reference BMI [69, 71–74, 76, 77, 79, 82], two publications
reported non-signiﬁcant inverse associations [75, 80] and three
publications reported no association [70, 78, 81] of BMI with
survival after breast cancer. Hence, 79 publications from 82
follow-up studies with 41 477 deaths (23 182 from breast
cancer) in 213 075 breast cancer survivors were included in the
meta-analyses (Figure 1). Supplementary Table S1, available at
Annals of Oncology online shows the characteristics of the
studies included in the meta-analyses and details of the excluded
studies are in supplementary Table S2, available at Annals of
Oncology online. Results of the meta-analyses are summarised
in Table 1.
Studies were follow-up of women with breast cancer iden-
tiﬁed in prospective aetiologic cohort studies (women were free
of cancer at enrolment), or cohorts of breast cancer survivors
whose participants were identiﬁed in hospitals or through
cancer registries, or follow-up of breast cancer patients enrolled
in case–control studies or randomised clinical trials.
Some studies included only premenopausal women [83–85]
or postmenopausal women [21, 27, 86–94], but most studies
included both. Menopausal status was usually determined at
time of diagnosis. Year of diagnosis was from 1957–1965 [70] to
2002–2009 [74]. Patient tumour characteristics and stage of
disease at diagnosis varied across studies, and some studies
included carcinoma in situ. No all studies provided clinical in-
formation on the tumour, treatment, and co-morbidities.
22 590 unique records identified in MEDLINE
and EMBASE until 30 June 2013
19 articles found in handsearch
1043 full-text articles retrieved and assessed
for inclusion
392 potentially relevant articles in women
with breast cancer
124 articles on body fatness and mortality
79 relevant articles (82 studies) on body
mass index and mortality included in the
meta-analyses in present review
31 articles excluded in present review
268 articles did not investigate body
fatness and mortality
651 articles excluded for not fulfilling the
inclusion criteria
87 no original data
338 did not report on the associations of
interest
33 abstract/commentary
10 meta-analyses
183 irrelevant study design
4 examined obesity index
12 no measure of association
14 articles excluded in meta-analysis
5 insufficient data
8 unadjusted results
15 superseded publications
21 566 records excluded on the basis of title
and abstract
Figure 1. Flowchart of search.
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Table 1. Summary of meta-analyses of BMI and survival in women with breast cancera
BMI before diagnosis BMI <12 months after diagnosis BMI ≥12 months after diagnosis
N RR (95% CI) I2 (%)
Ph
N RR (95% CI) I2 (%)
Ph
N RR (95% CI) I2 (%)
Ph
Total mortality
Under versus normal weight 10 1.10 (0.92–1.31) 48%
0.04
11 1.25 (0.99–0.57) 63%
<0.01
3 1.29 (1.02–1.63) 0%
0.39
Over versus normal weight 19 1.07 (1.02–1.12) 0%
0.88
22 1.07 (1.02–1.12) 21%
0.18
4 0.98 (0.86–1.11) 0%
0.72
Obese versus normal weight 21 1.41 (1.29–1.53) 38%
0.04
24 1.23 (1.12–1.33) 69%
<0.01
5 1.21 (1.06–1.38) 0%
0.70
Obese versus non-obese – – – 12 1.26 (1.07–1.47) 80%
<0.01
– – –
Per 5 kg/m2 increase 15 1.17 (1.13–1.21) 7%
0.38
12 1.11 (1.06–1.16) 55%
0.01
4 1.08 (1.01–1.15) 0%
0.52
Breast cancer mortality
Under versus normal weight 8 1.02 (0.85–1.21) 31%
0.18
5 1.53 (1.27–1.83) 0%
0.59
1 1.10 (0.15–8.08) –
Over versus normal weight 21 1.11 (1.06–1.17) 0%
0.66
12 1.11 (1.03–1.20) 14%
0.31
2 1.37 (0.96–1.95) 0%
0.90
Obese versus normal weight 22 1.35 (1.24–1.47) 36%
0.05
12 1.25 (1.10–1.42) 53%
0.02
2 1.68 (0.90–3.15) 67%
0.08
Obese versus non-obese – – – 6 1.26 (1.05–1.51) 64%
0.02
– – –
Per 5 kg/m2 increase 18 1.18 (1.12–1.25) 47%
0.01
8 1.14 (1.05–1.24) 66%
0.01
2 1.29 (0.97–1.72) 64%
0.10
Cardiovascular disease related mortality
Over versus normal weight 2 1.01 (0.80–1.29) 0%
0.87
– – – – – –
Obese versus normal weight 2 1.60 (0.66–3.87) 78%
0.03
– – – – – –
Per 5 kg/m2 increase 2 1.21 (0.83–1.77) 80%
0.03
– – – – – –
Non-breast cancer mortality
Over versus normal weight – – – 5 0.96 (0.83–1.11) 26%
0.25
– – –
Obese versus normal weight – – – 5 1.29 (0.99–1.68) 72%
0.01
– – –
aBMI before and after diagnosis (<12 months after, or ≥12 months after diagnosis) was classiﬁed according to the exposure period which the studies referred to in the BMI assessment; the BMI categories
were included in the categorical meta-analyses as deﬁned by the studies.
Ph, P for heterogeneity between studies.
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Most of the studies were based in North America or Europe.
There were three studies from each of Australia [79, 95, 96],
Korea [97, 98] and China [99–101]; two studies from Japan [71,
102]; one study from Tunisia [103] and four international
studies [19, 104–106]. Study size ranged from 96 [107] to
24 698 patients [97]. Total number of deaths ranged from 56
[93] to 7397 [108], and the proportion of deaths from breast
cancer ranged from 22% [27] to 98% [84] when reported. All
but eight studies [30, 93, 94, 98, 99, 109–111] had an average
follow-up of more than 5 years.
Study
Underweight v normal weight
Buck 2011
Conroy 2011
Lu 2011
Chen 2010
Emaus 2010
Hellmann 2010
Nichols 2009
Conroy 2011
Lu 2011
Chen 2010
Emaus 2010
Hellmann 2010
Keegan 2010
Nichols 2009
West-Wright 2009
Caan 2008
Dal Maso 2008
Reding 2008
Reeves 2007
Abrahamson 2006
Kroenke 2005
Reeves 2000
Zhang 1995
Holmberg 1994
Abrahamson 2006
Kroenke 2005
Bernstein 2002
Subtotal (I-squared = 48.2%, P = 0.043)
Subtotal (I-squared = 0.0%, P = 0.882)
.
Overweight v normal weight
Kamineni 2013
Buck 2011
Conroy 2011
Lu 2011
Chen 2010
Emaus 2010
Hellmann 2010
Keegan 2010
Nichols 2009
West-Wright 2009
Caan 2008
Dal Maso 2008
Reding 2008
Reeves 2007
Cleveland 2007
Abrahamson 2006
Kroenke 2005
Reeves 2000
Bernstein 2002
Zhang 1995
Holmberg 1994
Subtotal (I-squared = 37.6%, P = 0.043)
0.125 1 8
.
Obese v normal weight
Kamineni 2013
Buck 2011
1.98 (0.79, 4.96)
1.13 (0.89, 1.42)
0.89 (0.70, 1.14)
1.44 (0.88, 2.37)
1.70 (0.86, 3.33)
1.36 (0.87, 2.11)
1.75 (0.94, 3.25)
1.15 (0.93, 1.42)
0.99 (0.84, 1.15)
1.02 (0.81, 1.27)
1.02 (0.81, 1.27)
1.22 (0.92, 1.61)
1.16 (0.92, 1.45)
1.13 (0.90, 1.42)
0.98 (0.78, 1.24)
1.20 (0.80, 1.70)
1.02 (0.83, 1.25)
1.20 (0.90, 1.60)
1.02 (0.94, 1.12)
1.47 (0.96, 2.24)
1.11 (0.91, 1.34)
1.19 (0.92, 1.53)
1.00 (0.50, 2.20)
2.38 (0.84, 6.77)
0.73 (0.52, 1.04)
0.89 (0.70, 1.13)
1.13 (0.43, 2.97)
1.10 (0.92, 1.31)
3.29
17.23
16.79
8.51
5.44
9.79
6.21
12.75
16.98
3.01
100.00
<18.5 v 18.5–24.9
<22.5 v 22.5–24.9
<20 v 20–24.9
<=18.4 v 18.5–24.9
<
<=19.9 v 20–25
<=18.4 v 18.5–24.9
<=18.4 v 18.5–24.9
<21 v 21–22
<=18.4 v 18.5–24.9
1.07 (1.02, 1.12)
1.09 (0.69, 1.72)
1.03 (0.69, 1.56)
1.54 (1.23, 1.91)
1.23 (1.04, 1.47)
1.58 (1.13, 2.22)
1.47 (1.08, 1.99)
1.61 (1.12, 2.33)
1.21 (1.00, 1.48)
1.52 (1.17, 1.98)
1.42 (1.08, 1.88)
1.60 (1.10, 2.30)
1.29 (0.99, 1.68)
1.90 (1.40, 2.50)
1.06 (0.86, 1.30)
1.63 (1.08, 2.45)
2.93 (1.37, 6.29)
1.20 (0.95, 1.52)
1.49 (1.18, 1.86)
1.18 (0.81, 1.72)
1.50 (0.70, 2.90)
5.93 (1.98, 17.80)
1.41 (1.29, 1.53)
1.31 (0.77, 2.22)
1.15 (0.54, 2.46)
7.31
8.97
4.42
5.05
3.94
8.12
6.06
5.70
3.90
6.02
5.39
7.67
3.34
1.16
6.85
7.08
3.78
1.31
0.58
100.00
2.20
1.17
>=30 v 22.5–24.9
>=30 v 20–24.9
>=30 v 18.5–24.9
>=30 v 18.5–24.9
>30 v 20–25
>=30 v <=24.9
>=30 v 18.5–24.9
>=30 v <25
>=30 v <=24.9
>=30 v <=24.9
>=25.8 v <=20.6
>=30 v 18.5–25
>30 v <24.9
>=30 v 18.5–24.9
>=30 v 21–22
>=27 v <=24
>25 v 18.5–24.9
28.9–45.9 v 16–24.6
>=29 v <19
>=30 v <25
>=30 v 18.5–24.9
.
RR (95% Cl)
%
Weight
BMI
kg/m2
=18.4 v 18.5–24.9
5.47
9.94
4.85
4.85
3.13
4.74
4.71
4.56
1.73
5.85
2.96
32.20
1.37
6.55
3.79
0.45
0.23
100.00
1.18
1.47
25–29.9 v 22.5–24.9
25–29.9 v 20–24.9
25–29.9 v 18.5–24.9
25–29.9 v 18.5–24.9
25.1–30 v 20–25
25–29.9 v <=24.9
25–29.9 v 18.5–24.9
25–29 v <=24
25–29.9 v <=24.9
25–29.9 v <=24.9
>22.4–25.8 v <–20.6
25–<30 v 18.5–<25
25–29.9 v 18.5–24.9
25–29 v 21–22
25–26 v <=24
24.7–28.8 v 16–24.6
25–28 v <19
25–29.9 v <25
25–29.9 v 18.5–24.9
Figure 2. Categorical meta-analysis of pre-diagnosis BMI and total mortality.
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BMI and total mortality
categorical meta-analysis. For BMI before diagnosis, compared
with normal weight women, the summary RRs were 1.41 (95%
CI 1.29–1.53, 21 studies) for obese women, 1.07 (95% CI 1.02–
1.12, 19 studies) for overweight women, and 1.10 (95% CI 0.92–
1.31, 10 studies) for underweight women (Figure 2). For BMI
<12 months after diagnosis and the same comparisons, the
summary RRs were 1.23 (95% CI 1.12–1.33, 24 studies) for
obese women, 1.07 (95% CI 1.02–1.12, 22 studies) for
overweight women, and 1.25 (95% CI 0.99–1.57, 11 studies) for
underweight women (supplementary Figure S1, available at
Annals of Oncology online). Substantial heterogeneities were
observed between studies of obese women and underweight
women (I2 = 69%, P < 0.01; I2 = 63%, P < 0.01, respectively). For
BMI ≥12 months after diagnosis, the summary RRs were 1.21
(95% CI 1.06–1.38, 5 studies) for obese women, 0.98 (95% CI
0.86–1.11, 4 studies) for overweight women, and 1.29 (95% CI
1.02–1.63, 3 studies) for underweight women (supplementary
Figure S2, available at Annals of Oncology online). Twelve
additional studies reported results for obese versus non-obese
women <12 months after diagnosis, and the summary RR was
1.26 (95% CI 1.07–1.47, I2 = 80%, P < 0.01).
dose–response meta-analysis. There was evidence of a J-shaped
association in the non-linear dose–response meta-analyses of
BMI before and after diagnosis with total mortality (all P < 0.01;
2 3
2
1
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R
R
R
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Best fitting fractional polynomial
95% confidence interval
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95% confidence interval
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95% confidence interval
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95% confidence interval
Best fitting fractional polynomial
95% confidence interval
BMI (kg/m2)
BMI (kg/m2)
BMI (kg/m2)
15 20 25 30 35 40
BMI (kg/m2)
BMI (kg/m2)
Total mortality
Pre-diagnosis BMI
BMI <12 months after diagnosis BMI <12 months after diagnosis
BMI >12 months after diagnosisBMI >12 months after diagnosis
Breast cancer mortality
Pre-diagnosis BMI
P < 0.001
P = 0.007
P < 0.001 P = 0.86
P = 1.00
P = 0.21
30 35 40 15 20 25
BMI (kg/m2)
30 35 40
Figure 3. Non-linear dose–response curves of BMI and mortality.
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Figure 3), suggesting that underweight women may be at
slightly increased risk compared with normal weight women.
The curves show linear increasing trends from 20 kg/m2 for
BMI before diagnosis and <12 months after diagnosis, and from
25 kg/m2 for BMI ≥12 months after diagnosis. When linear
models were ﬁtted excluding the underweight category, the
summary RRs of total mortality for each 5 kg/m2 increase in
BMI were 1.17 (95% CI 1.13–1.21, 15 studies, 6358 deaths), 1.11
(95% CI 1.06–1.16, 12 studies, 6020 deaths), and 1.08 (95% CI
1.01–1.15, 4 studies, 1703 deaths) for BMI before, <12 months
after, and ≥12 months after diagnosis, respectively (Figure 4).
Substantial heterogeneity was observed between studies on BMI
<12 months after diagnosis (I2 = 55%, P = 0.01).
BMI and breast cancer mortality
categorical meta-analysis. BMI was signiﬁcantly associated
with breast cancer mortality. Compared with normal weight
women, for BMI before diagnosis, the summary RRs were 1.35
(95% CI 1.24–1.47, 22 studies) for obese women, 1.11 (95% CI
1.06–1.17, 21 studies) for overweight women, and 1.02 (95% CI
0.85–1.21, 8 studies) for underweight women (Figure 5). For
BMI <12 months after diagnosis, the summary RRs were 1.25
(95% CI 1.10–1.42, 12 studies) for obese women, 1.11 (95% CI
1.03–1.20, 12 studies) for overweight women, and 1.53 (95% CI
1.27–1.83, 5 studies) for underweight women (supplementary
Figure S3, available at Annals of Oncology online). Substantial
heterogeneity was observed between studies of obese women
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Figure 4. Linear dose–response meta-analysis of BMI and total mortality.
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(I2 = 53%, P = 0.02). For BMI ≥12 months after diagnosis, the
summary RRs of the two studies identiﬁed were 1.68 (95% CI
0.90–3.15) for obese women and 1.37 (95% CI 0.96–1.95) for
overweight women (supplementary Figure S4, available at
Annals of Oncology online). The summary of another six studies
that reported RRs for obese versus non-obese <12 months after
diagnosis was 1.26 (95% CI 1.05–1.51, I2 = 64%, P = 0.02).
dose–response meta-analysis. There was no signiﬁcant evidence
of a non-linear relationship between BMI before, <12 months
after, and ≥12 months after diagnosis and breast cancer
mortality (P = 0.21, P = 1.00, P = 0.86, respectively) (Figure 3).
When linear models were ﬁtted excluding data from the
underweight category, statistically signiﬁcant increased risks of
breast cancer mortality with BMI before and <12 months after
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Figure 5. Categorical meta-analysis of pre-diagnosis BMI and breast cancer mortality.
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diagnosis were observed (Figure 6). The summary RRs for each
5 kg/m2 increase were 1.18 (95% CI 1.12–1.25, 18 studies, 5262
breast cancer deaths) for BMI before diagnosis and 1.14 (95%
CI 1.05–1.24, 8 studies, 3857 breast cancer deaths) for BMI <12
months after diagnosis, with moderate (I2 = 47%, P = 0.01) and
substantial (I2 = 66%, P = 0.01) heterogeneities between studies,
respectively. Only two studies on BMI ≥12 months after
diagnosis and breast cancer mortality (N = 220 deaths) were
identiﬁed. The summary RR was 1.29 (95% CI 0.97–1.72).
BMI and other mortality outcomes
Only two studies reported results for death from cardiovascular
disease (N = 151 deaths) [27, 112]. The summary RR for
obese versus normal weight before diagnosis was 1.60 (95% CI
0.66–3.87). No association was observed for overweight versus
normal weight (summary RR = 1.01, 95% CI 0.80–1.29). For each
5 kg/m2 increase in BMI, the summary RR was 1.21 (95% CI
0.83–1.77). Five studies reported results for deaths from any cause
other than breast cancer (N = 2704 deaths) [21, 34, 108, 113, 114].
The summary RRs were 1.29 (95% CI 0.99–1.68, I2 = 72%,
P = 0.01) for obese women, and 0.96 (95% CI 0.83–1.11, I2 = 26%,
P = 0.25) for overweight women compared with normal weight
women.
subgroup, meta-regression, and sensitivity
analyses
The results of the subgroup and meta-regression analyses are in
supplementary Tables S3 and S4, available at Annals of
Oncology online. Subgroup analysis was not carried out for BMI
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Figure 6. Linear dose–response meta-analysis of BMI and breast cancer mortality.
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≥12 months after diagnosis as the limited number of studies
would hinder any meaningful comparisons.
Increased risks of mortality were observed in the meta-ana-
lyses by menopausal status. While the summary risk estimates
seem stronger with premenopausal breast cancer, there was no
signiﬁcant heterogeneity between pre- and post-menopausal
breast cancer as shown in the meta-regression analyses
(P = 0.28–0.89) (supplementary Tables S3 and S4, available at
Annals of Oncology online). For BMI before diagnosis and total
mortality, the summary RRs for obese versus normal weight
were 1.75 (95% CI 1.26–2.41, I2 = 70%, P < 0.01, 7 studies) in
women with pre-menopausal breast cancer and 1.34 (95% CI
1.18–1.53, I2 = 27%, P = 0.20, 9 studies) in women with post-
menopausal breast cancer.
Studies with larger number of deaths [105, 115], conducted in
Europe [28, 115], or with weight and height assessed through
medical records [28, 104, 115, 116] tended to report weaker
associations for BMI <12 months after diagnosis and total mor-
tality compared with other studies (meta-regression P = 0.01,
0.02, 0.01, respectively) (supplementary Table S3, available at
Annals of Oncology online); while studies with larger number of
deaths [101], conducted in Asia [101, 102], or adjusted for
co-morbidity [101, 102] reported weaker associations for BMI
<12 months after diagnosis and breast cancer mortality (meta-
regression P = 0.01, 0.02, 0.01, respectively) (supplementary
Table S4, available at Annals of Oncology online).
Analyses stratiﬁed by study designs, or restricted to studies
with invasive cases only, early-stage non-metastatic cases only,
or mammography screening detected cases only, or controlled
for previous diseases did not produce results that were material-
ly different from those obtained in the overall analyses (results
not shown). Summary risk estimates remained statistically sign-
iﬁcant when each study was omitted in turn, except for BMI
≥12 months after diagnosis and total mortality. The summary
RR was 1.06 (95% CI 0.98–1.15) per 5 kg/m2 increase when
Flatt et al. [117] which contributed 315 deaths was omitted.
small studies or publication bias
Asymmetry was only detected in the funnel plots of BMI <12
months after diagnosis and total mortality, and breast cancer
mortality, which suggests that small studies with an inverse
association are missing (plots not shown). Egger’s tests
were borderline signiﬁcant (P = 0.05) or statistically signiﬁcant
(P = 0.03), respectively.
discussion
The present systematic literature review and meta-analysis of
follow-up studies clearly supports that, in breast cancer survi-
vors, higher BMI is consistently associated with lower overall
and breast cancer survival, regardless of when BMI is ascer-
tained. The limited number of studies on death from cardiovas-
cular disease is also consistent with a positive association. For
before, <12 months after, and 12 months or more after breast
cancer diagnosis, compared with normal weight women, obese
women had 41%, 23%, and 21% higher risk for total mortality,
and 35%, 25%, and 68% increased risk for breast cancer mortal-
ity, respectively. The ﬁndings were supported by the positive
associations observed in the linear dose–response meta-analysis.
All associations were statistically signiﬁcant, apart from the rela-
tionship between BMI ≥12 months after diagnosis and breast
cancer mortality. This may be due to limited statistical power,
with only 220 breast cancer deaths from two follow-up studies.
Positive associations, in some cases statistically signiﬁcant, were
also observed in overweight, and underweight women compared
with normal weight women. Women with BMI of 20 kg/m2
before, or <12 months after diagnosis, and of 25 kg/m2
12 months or more after diagnosis appeared to have the lowest
mortality risk in the non-linear dose–response analysis. Co-
morbid conditions may cause the observed increased risk in
underweight women. Thorough investigation within the group
and on their contribution to the shape of the association is hin-
dered, as not all studies in this review reported results for this
group. The increased risk associated with obesity was similar in
pre- or post-menopausal breast cancer. We did not ﬁnd any
evidence of a protective effect of obesity on survival after pre-
menopausal breast cancer, contrary to what has been
observed for the development of breast cancer in pre-menopausal
women [4].
A large body of evidence with 41 477 deaths (23 182 from
breast cancer) in over 210 000 breast cancer survivors was sys-
tematically reviewed in the present study. We carried out cat-
egorical, linear, and non-linear dose–response meta-analyses to
examine the magnitude and the shape of the associations for
total and cause-speciﬁc mortality in underweight, overweight,
and obese women by time periods before and after diagnosis
that is important in relation to the population-at-risk and breast
cancer survivors. Our ﬁndings agree with and further extend the
results from previous meta-analyses. A review published in 2010
reported statistically signiﬁcant increased risks of 33% of both
total and breast cancer mortality for obesity versus non-obesity
around diagnosis [7]. These estimates are slightly higher than
ours, which may be explained by the different search periods
and inclusion criteria for the articles (33 studies and 15 studies
included in the analyses, respectively). Another review pub-
lished in 2012 further reported consistent positive associations
of total and breast cancer mortality with higher versus lower
BMI around diagnosis [6]. No signiﬁcant differences were
observed by menopausal status or hormone receptor status. The
After Breast Cancer Pooling Project of four prospective cohort
studies found differential effects of levels of pre-diagnosis
obesity on survival [118]. Compared with normal weight
women, signiﬁcant or borderline signiﬁcant increased risks of
81% of total and 40% of breast cancer mortality were only
observed for morbidly obese (≥40 kg/m2) women and not for
women in other obesity categories. We observed statistically
signiﬁcant increased risks also for overweight women, probably
because of a larger number of studies. We were unable to investi-
gate the associations with severely and morbidly obese women
because only two studies included in this review reported such
results [19, 113]. Overall, our ﬁndings are consistent with previ-
ous meta-analyses in showing elevated total and breast cancer
mortality associated with higher BMI and support the current
guidelines for breast cancer survivors to stay as lean as possible
within the normal range of body weight [4], for overweight
women to avoid weight gain during treatment and for obese
women to lose weight after treatment [119].
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The present review is limited by the challenges and ﬂaws
encountered by the individual epidemiological studies evaluating
the body fatness–mortality relationship in breast cancer survivors.
Most studies did not adjust for co-morbidities and assess inten-
tional weight loss. Women with more serious health issues, and
especially smokers, may lose weight but are at an increased risk of
mortality, and this might cause an apparent increased risk in
underweight women. Body weight information through the
natural history of the disease and treatment information were
usually not complete or available. Increase of body weight post-
diagnosis is common in women with breast cancer, particularly
during chemotherapy [16]. Chemotherapy under-dosing is a
common problem in obese women and may contribute to their
increased mortality [120]. Although several studies with pre-diag-
nosis BMI adjusted for underlying illnesses or excluded the ﬁrst
few years of follow-up, reverse causation may have affected the
results in studies that assessed BMI in women with cancer and
other illnesses. However, in these studies, the associations were
similar to other studies. Possible survival beneﬁt (subjects with
better prognostic factors survive) may be present in the survival
cohorts, in which the range of BMI could be narrower, and may
cause an underestimation of the association.
Follow-up studies with variable characteristics were pooled in
the meta-analysis. Women identiﬁed in clinical trials may have
had speciﬁc tumour subtypes, with fewer co-morbidities, and
were more likely to receive protocol treatments with high treat-
ment completion rates. Women who were recruited through
mammography screening programmes may have had healthier
lifestyles or access to medical facilities, and more likely to be
diagnosed with in situ or early-stage breast cancer. Cancer de-
tection methods, tumour classiﬁcations and treatment regimens
change over time, and may vary within (if follow-up is long) and
between studies, and could not be simply examined by using the
diagnosis or treatment date. We cannot rule out the effect of un-
measured or residual confounding in our analysis. Nevertheless,
most results were adjusted for multiple confounding factors, in-
cluding tumour stage or other-related variables and stratiﬁed
analyses by several key factors showed similar summary risk
estimates. Small study or publication bias was observed in the
analyses of BMI
<12 months after diagnosis. However, the overall evidence is
supported by large, well-designed studies and is unlikely to be
changed. We did not conduct analyses by race/ethnicity and
treatment types as only limited studies had published results.
Future studies of body fatness and breast cancer outcomes
should aim to account for co-morbidities, separate intended and
unintended changes of body weight, and collect complete treat-
ment information during study follow-up. Randomised clinical
trials are needed to test interventions for weight loss and main-
tenance on survival in women with breast cancer.
In conclusion, the present systematic literature review and
meta-analysis extends and conﬁrms the associations of obesity
with an unfavourable overall and breast cancer survival in pre-
and post-menopausal breast cancer, regardless of when BMI is
ascertained. Increased risks of mortality in underweight and
overweight women were also observed. Given the comparable
elevated risks with obesity in the development (for post-
menopausal women) and prognosis of breast cancer, and the
complications with cancer treatment and other obesity-related
co-morbidities, it is prudent to maintain a healthy body weight
(BMI 18.5–<25.0 kg/m2) throughout life.
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Prediction of treatment-related toxicity and outcome
with geriatric assessment in elderly patients with solid
malignancies treated with chemotherapy: a systematic
review
K. S. Versteeg1, I. R. Konings1, A. M. Lagaay2, A. A. van de Loosdrecht3 & H. M. W. Verheul1*
1Department of Medical Oncology, VU University Medical Center, Amsterdam; 2Department of Internal Medicine, Spaarne Hospital, Hoofddorp; 3Department
of Hematology, VU University Medical Center, Amsterdam, The Netherlands
Received 10 July 2013; revised 9 December 2013 & 3 February 2014; accepted 4 February 2014
Introduction: The number of older patients with cancer is increasing. Standard clinical evaluation of these patients may
not be sufﬁcient to determine individual treatment strategies and therefore Geriatric Assessment (GA) may be of clinical
value. In this review, we summarize current literature that is available on GA in elderly patients with solid malignancies who
receive chemotherapy. We focus on prediction of treatment toxicity, mortality and the role of GA in the decision-making
process.
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